MARKET

NRBO

NRBO

NeuroBo Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.21
-0.89
-9.78%
Closed 16:00 01/24 EST
OPEN
9.33
PREV CLOSE
9.10
HIGH
9.33
LOW
8.21
VOLUME
9.11K
TURNOVER
--
52 WEEK HIGH
37.13
52 WEEK LOW
5.95
MARKET CAP
4.88M
P/E (TTM)
-0.0136
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NRBO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

NRBO News

  • NeuroBo Pharmaceuticals to Present at Biotech Showcase 2020 in San Francisco
  • Business Wire.01/13 14:00
  • NeuroBo Pharmaceuticals and Gemphire Therapeutics Complete Merger
  • Business Wire.01/10 22:00
  • Gemphire Therapeutics Announces Expected Closing Date of Merger with NeuroBo Pharmaceuticals
  • GlobeNewswire.12/30/2019 16:08
  • Gemphire's stockholder approves NeuroBo merger proposals
  • Seeking Alpha - Article.12/06/2019 14:06

More

Industry

Biotechnology & Medical Research
-2.12%
Pharmaceuticals & Medical Research
-2.17%

Hot Stocks

Name
Price
%Change

About NRBO

NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. The Company is focused on developing pharmaceuticals to treat neurodegenerative disorders. The Company is addressing unmet needs in patients with Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease. The Company’s product candidate, NB-01, is targeting neuropathic pain with an indication in PDN. The Company also provides NB-02, which is an Alzheimer’s and tauopathies drug.
More

Webull offers Neurobo Pharmaceuticals Inc (NRBO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.